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Biphosphonates for the therapy of complex regional pain
syndrome I - systematic review
Abstract
OBJECTIVES: Several studies found that biphosphonates counteract locally increased bone resorption
and associated pain in patients with complex regional pain syndrome I (CRPS I). We performed a
systematic review of all randomised controlled trials to assess the benefit of biphosphonates in the
treatment of CRPS I patients with bone loss. DATA SOURCES: We searched Medline, Embase (April
2007) and the Cochrane Library and screened bibliographies of included studies. REVIEW METHODS:
We selected randomised trials comparing biphosphonates with placebo, with the goal of improving pain,
function and quality of life in patients with CRPS I. Two reviewers independently assessed trial
eligibility and quality, and extracted data. Where data were incomplete or unclear, conflicts were
resolved with discussion and/or trial authors were contacted for further details. We calculated the study
size weighted pooled mean reduction of pain intensity (measured with a visual analogue scale (VAS)).
RESULTS: Four trials of moderate quality fulfilled our inclusion criteria. In respect to function and
quality of life there was a trend in favour of biphosphonates but differences in outcome assessment
impeded pooling of results. Two trials provided sufficient data to pool pain outcomes. Biphosphonates
reduced pain intensity by 22.4 and 21.6mm on a VAS after 4 and 12 weeks of follow-up. Data on
adverse effects were scarce. CONCLUSIONS: The very limited data reviewed showed that
bisphosphonates have the potential to reduce pain associated with bone loss in patients with CRPS I.
However, at present there is not sufficient evidence to recommend their use in practice.
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Abstract 
 
Objectives  Serveral studies found that biphosphonates counteract locally increased bone 
resorption and associated pain in patients with complex regional pain syndrome I (CRPS 
I). We performed a systematic review of all randomised controlled trials to assess the 
benefit of biphosphonates in the treatment of CRPS I patients with bone loss. 
Data sources We searched Medline, Embase (April 2007) and the Cochrane Library and 
screened bibliographies of included studies.  
Review methods We selected randomised trials comparing biphosphonates with placebo, 
with the goal of improving pain, function and quality of life in patients with CRPS I. Two 
reviewers independently assessed trial eligibility and quality, and extracted data. Where 
data were incomplete or unclear, conflicts were resolved with discussion and/or trial 
authors were contacted for further details. We calculated the study size weighted pooled 
mean reduction of pain intensity (measured with a visual analogue scale (VAS)). 
Results Four trials of moderate quality fulfilled our inclusion criteria. In respect to function 
and quality of life there was a trend in favour of biphosphonates but differences in outcome 
assessment impeded pooling of results. Two trials provided sufficient data to pool pain 
outcomes. Biphosphonates reduced pain intensity by 22.4 and 21.6 mm on a VAS after 4 
and 12 weeks of follow-up. Data on adverse effects were scarce.  
Conclusions The very limited data reviewed showed that bisphosphonates have the 
potential to reduce pain associated with bone loss in patients with CRPS I. However, at 
present there is not sufficient evidence to recommend their use in practice.  
250 words 
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Introduction 
 
Complex regional pain syndrome I (CRPS I) is a common, disabling and poorly 
understood disorder (Kock et al. 2003). The syndrome is characterized by pain and various 
combinations of autonomic, sensory, motor, and trophic changes (Veldman et al. 1993; 
Merskey and Bogduk 1994; Bruehl et al. 1999). The precise causes of CRPS I are 
unknown; it often develops after a trauma, such as an injury or surgery (Maihofner and 
Birklein 2007). 
Due to the complexity of this disorder, involving the peripheral as well as the 
central neural system, there is no evidence of an effective treatment (Maihofner and 
Birklein 2007). No definite treatment algorithm has been established, although numerous 
therapeutic approaches have been described in the past with varying success (Forouzanfar 
et al. 2002). According to the currently available guidelines, treatment is usually based on 
a multimodal concept including medical treatment, physical therapy, occupational therapy 
and psychotherapy (Stanton-Hicks et al. 1998; Stanton-Hicks et al. 2002; Geertzen et al. 
2006; Harden 2006). 
Among other physical agents, the use of biphosphonates in the treatment of CRPS I 
was recommended when calcitonin is inefficient or when calcitonin injections are not well 
tolerated (Chauvineau et al. 2005). Biphosphonates are potent antiosteoclastic agents 
which are often used for the treatment of several bone related pathologies such as Paget’s 
disease, metastatic cancer, myeloma and acute vertebral fractures. 
CRPS I may be associated with a localized bone resorption in the affected limb 
which results from osteoclastic hyperactivity (Adami et al. 1997). Therefore, several 
authors hypothesized that the use of biphosphonates might be beneficial in the treatment of 
CRPS I because these agents counteract bone resorption and show some analgetic effect. 
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(Reviewed in (Schott 1997)) We set out to perform a systematic review of all randomized 
controlled trials testing the benefit of biphosphonates in CRPS I treatment and to 
summarize the value of this promising drug. 
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Methods 
 
This systematic review was performed applying rigorous published methods 
(Center for Reviews and Dissemination, Report 4, 2001). 
Identification of studies 
We searched Medline (PubMed Version) and Embase (Ovid® interface) from inception to 
April 2007 using the search terms Complex regional pain syndrome, CRPS, 
algoneurodystrophy, algodystrophy, shoulder-hand syndrome, reflex sympathetic 
dystrophy, RSD, and Sudeck. Searches in the Cochrane Central Register of Controlled 
Trials (2007, Issue 2) and screening bibliographies of all included studies complemented 
our searches. We imposed no language restrictions. We looked for randomised trials 
comparing biphosphonates with placebo, with the goal of improving pain, function and 
quality of life in patients with CRPS I. 
Study selection 
One reviewer (FB) designed the search strategy and performed the searches. Two 
reviewers (FB and AS) independently screened the titles, keywords and abstracts of all 
retrieved records against the inclusion criteria. They looked for randomised studies 
including patients with the diagnosis of CRPS 1 and comparing biphosphonates against 
placebo. Then, the reviewers assessed the full text of potentially eligible papers to ascertain 
that the studies met the inclusion criteria. Disagreements on inclusion were resolved by 
discussion or through arbitration by a third reviewer (LMB). 
Data extraction 
Two reviewers (FB, AS) independently extracted the salient features from each trial using 
a data extraction form that was pretested using one included trial. From each study we 
secured setting (e.g. year, country of origin), number of participants, and site of CRPS, 
type of intervention, dosage and application mode and duration of intervention. We also 
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registered types of outcome measures, timing of outcome assessments and the 
corresponding results. Finally, we registered all published adverse effects. 
Assessment of study quality 
Two reviewers (FB, AS) independently evaluated the methodological quality of each 
included trial. Based on existing recommendations (Riet and Kessels 1997) we developed a 
quality assessment form. The form was piloted on the first paper to check for any 
misunderstandings when addressing the items and revised where necessary (see Appendix 
1). Disagreements were resolved by consensus. A third reviewer (LMB) arbitrated 
persisting disagreements. 
Statistical analysis 
In this study we assessed the agreement according to published recommendations between 
two reviewers using kappa statistics.(Kirkwood and Sterne 2006)  The kappa statistics is 
based on comparing the observed proportion of agreement between two readings (Aobs) 
made by the two testers, with the proportion of agreements that would be expected simply 
by chance (Aexp). 
Kappa=(Aobs-Aexp)/(1-Aexp) 
Landis and Koch propose the following interpretation of the kappa statistic: kappa > 0.75 
represents excellent agreement, values of kappa between 0.4 and 0.75 represent fair to 
good agreement, and kappa values less than 0.4 show moderate or poor agreement (Landis 
and Koch 1977). Where available, we calculated differences in outcome parameters from 
baseline per group and analysed differences between groups. We decided to pool the 
results of studies if they reported on the same outcome measure and timing. These data 
were only available for pain assessment using a visual analogue scale at four and twelve 
weeks of follow-up. Mean VAS differences were pooled using variance weights. 
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Results 
 
Our searches retrieved 1767 records from which 16 appeared to be potentially 
relevant. Full text assessment resulted in exclusion of 12 additional studies. In total four 
trials were included in this review (Adami et al. 1997; Varenna et al. 2000; Manicourt et al. 
2004; Robinson et al. 2004). (For study selection details please see figure 1). 
Description of studies 
In total 118 patients (intervention group n=59, control group n=59) with CRPS 1 were 
treated. All four RCT’s were small, including less than 30 patients in one study arm. Mean 
age was 51.7 years; mean disease duration was 12.5 months (range 3.5-21.6 months). The 
site of CRPS 1 was more in the lower extremity (n=89) than in the upper extremity (n=30). 
Trauma (n=38) and fracture (n=28) were the most frequent initiating events causing CRPS 
1. The participants were treated either with oral (n=1) (Manicourt et al. 2004) or 
intravenous administration (n=3) (Adami et al. 1997; Varenna et al. 2000; Robinson et al. 
2004) of a biphosphonate compound. Alendronate was used in two studies, pamidronate 
(Robinson et al. 2004) and clondronate (Varenna et al. 2000) were administered once. Side 
effects were evaluated in all 4 studies and were rare. 
The characteristics of the included trials are summarized in Table 1. 
Methodological quality of included studies 
The agreement between the two reviewers was excellent. (Agreement on 78 of the 88 item 
scores (89%); kappa = 0.80). No arbitration was necessary.  
All 4 included studies were considered to be of moderate quality (Table 2). 
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Evidence of improvement of quality of life and function 
Two studies showed a significant improvement of joint mobility (Adami et al. 1997; 
Manicourt et al. 2004). Due to different measures of range of motion, statistical pooling 
was not possible (goniometer (Manicourt et al. 2004) vs. arbitrary score (Adami et al. 
1997). One study showed a significant improvement of physical function in the treatment 
group by assessing SF-36 after 1 and 3 months (Robinson et al. 2004). None of the studies 
considered measuring the aspect of quality of life.  
Evidence of effectiveness 
Due to the variability in respect to interventions, enrolment criteria, control treatments, 
duration of follow-up visits and outcome measures, only two out of four studies were 
considered clinically comparable regarding pain intensity (VAS) after 4 and 12 weeks 
(Manicourt et al. 2004; Robinson et al. 2004). Statistical pooling showed a weighted 
average of -22.4 after 4 weeks and -21.6 after 12 weeks on a scale of 100. 
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Discussion 
 
Main findings 
This review has two findings. Evidence from trials investigating the effects of 
biphosphonates in CRPS I are still scarce. Pooled analysis of two small trials suggests that 
these agents have a favourable effect on pain management. In respect to other clinically 
relevant outcomes four studies show trends towards favourable effects but differences in 
trial design impede exhaustive quantitative assessments at this stage. 
Results in light of existing evidence 
In a narrative review published in 2005 in French, Chauvineau and colleagues (Chauvineau 
et al. 2005) made a first attempt to summarize the effects of biphosphonates in CRPS I 
treatment. In that review, which did not include a formal meta analysis, the authors felt that 
current evidence was insufficient to set proper indication for treatment or to estimate 
treatment effects (Chauvineau et al. 2005). The review did not apply up to date systematic 
review methodology, did not search all relevant electronic databases and was incomplete in 
respect to quality assessment. Since electronic searches were limited to 2003 they missed 
two studies (Manicourt et al. 2004; Robinson et al. 2004) out of which one study 
contributed data to our meta-analysis (Manicourt et al. 2004). On the other hand, 
Chauvineau and colleagues included two studies that we excluded from our analysis. The 
paper by Liens et al. (Liens et al. 1995) studied patients with questionable cases of CRPS I 
and the paper by Cohen and Uebelhart (Cohen and Uebelhart 1998) used an active control 
(calcitonin).  
Strength and limitations 
The strength of this study includes the application of robust systematic review 
methodology. We made strenuous efforts to minimize the risk of selection bias. Relevant 
reports were searched systematically and without language restriction. Also, we attempted 
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to perform a meta-analysis. But, due to the limited number of available studies, the 
variability in terms of study population, interventions, duration of follow-up and outcome 
measures, pooling of results was limited to pain intensity (VAS) after 4 and 12 weeks. 
Other clinically relevant outcomes such as improvements in range of motion, oedema and 
quality of life could not be assessed meta-analytically. In addition, all studies were rather 
small resulting in imprecise estimates.  
Implications for practice 
The current guideline published by a consensus report in 1998 does not recommend 
biphosphonates in CRPS I treatment. Stanton-Hicks et al. only recommend the use of 
subcutaneous calcitonin for a mild effect on spontaneous pain, the use of oral or 
intravenous biphosphonates was not part of their recommendations (Stanton-Hicks et al. 
1998). We think, that it is still too early to recommend broad application of biphosphonates 
in CRPS I management. Treatment should be initiated only within research protocols that 
clearly define exposures, and involve standardised outcome assessments. Moreover, 
treatment regimens should always be based on a multidisciplinary approach rather than the 
use of a single medication. 
Conclusions 
In conclusion, the very limited data reviewed showed that bisphosphonates have the 
potential to reduce pain in patients with CRPS I. However, at present there is not sufficient 
evidence to recommend their use in practice. To prove the possible beneficial effect in 
reducing pain, we recommend high quality randomised studies with clear inclusion and 
exclusion criteria and with a sufficient sample size. The outcome measures should include 
overall improvement in function and decreasing pain, quality of health status, return to 
work and side effect. In addition, optimum dosage, frequency and duration of treatment 
must be further examined. 
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Table 1: Characteristics of included trials 
Table 2: Methodological quality assessment of included studies 
Figure 1: Study flow from identification to final inclusion of studies 
 
Point-by-point reply for EJP-D-07-00267 
 
 
# 
 
 
Reviewer 1 
  
Our reply 
    
1 This is a systematic review on the topic of 
biphosphanates for CRPS. 
 
 No reply required. 
2 Presentation is peculiar because most of the 
data from analysis is presented in the abstract 
and not at all in the result section and it was 
not discussed much, such as topics of function 
and quality of life. Those are very important 
issue and should be discussed in the text of 
the manuscript. 
 
 We agree with reviewer 1 and added a paragraph 
summarizing the outcome parameters in respect 
to function and quality of life (see p8, 1 para. 
“Two studies showed a significant 
improvement of joint mobility (Adami et al. 
1997; Manicourt et al. 2004). Due to different 
measures of range of motion, statistical pooling 
was not possible (goniometer (Manicourt et al. 
2004) vs. arbitrary score (Adami et al. 1997). 
One study showed a significant improvement 
of physical function in the treatment group by 
assessing SF-36 after 1 and 3 months 
(Robinson et al. 2004). None of the studies 
considered measuring the aspect of quality of 
life.” 
 
3 In conclusion, second sentence, authors state 
"pain associated with bone loss" - was bone 
loss measured in all of those studies?  Was 
bone density studied? Please explain. 
 Reviewer 1 raises an important issue. Previous 
research speculated that pain in patients with 
CRPS 1 may be caused by localized bone 
resorption (Adami et al., 1997). One argument in 
favor of this assumption is the results of our 
Meta-analysis which revealed a possible analgetic 
effect by the use of biphosphonates. However, we 
agree with Reviewer 1 that our understanding of 
the causal pathway remains ill understood at 
present. To clarify this point we decided to soften 
the statement in the conclusion section. The 
revised abstract reads as follows: “In conclusion, 
the very limited data reviewed showed that 
bisphosphonates have the potential to reduce 
pain in patients with CRPS I.” Accordingly we 
also revised the the statement in the conclusion 
section of the main text.  
 
4 Page 7. paragraph 2, line 4, "cite" and it 
should be "site." 
 
 Well spotted, thank you! We corrected this typo.  
    
# Reviewer #2 
 
  
Revision Notes
1 The authors have performed a systematic 
review on the effect of biphosphonates in 
CRPS I. Recently another review of the 
subject was published. That paper was in 
French and since that one more RCT has been 
published. The authors discuss the French 
paper and argue on shortcomings in 
methodology of that paper. 
 
 No reply required. 
 
2 
 
The number or RCTs that the conclusions are 
based on are still few (4), and no new 
recommendations for the use of 
biphosphonates in CRPS-I are given. The 
authors recommend high quality randomised 
studies before beneficial effects could be 
proven. Thus this paper does not contribute 
very much to what could be recommended in 
clinical care. However, the study is well 
designed and there is not previously a 
systematic review on this subject in the 
English literature. 
 
  
We would like to thank Reviewer 2 for the 
complaisant assessment of our paper. We agree 
that the results of this review do not have an 
impact on daily clinical practice. Unfortunately 
this is commonly the case. Systematic reviews 
tend to call for more studies, and more than half 
of completed Cochrane reviews state that the 
evidence in support of the intervention is limited 
or poor (Ann Intern Med. 2007 Aug 
21;147(4):273-4.). A systematic review might 
still be useful if it raises awareness and provides 
an overview of the existing evidence in an 
emgerging new field of research. Moreover, to 
our knowledge, this is the first attempt to perform 
a meta-analysis on this. 
 
3 Figure 1. Citations excluded after screening: 
1767 - total citations identified: 1751. 
 
 Thank you, well spotted! We revised Figure 1 
accordingly: Total citations identified: 1767, 
citations excluded after screening: 1751. 
 
4 Tables are not numbered.  Thank you. We numbered the figure as well as 
the tables. 
 
5 Table 2 includes an unnecessary repetition on 
the items used for the quality control. Or was 
this supposed to be the appendix? 
 
 We agree with Reviewer #2 and dropped 
Appendix 1. 
6 References.  
Center for Reviews and dissemination, Report 
4, 2001 Cochrane Central register. 
To be retrievable for the reader these 
references should be fully presented in the 
reference list. 
 We agree and added the following reference to 
the reference list: Center for Reviews and 
dissemination, Report 4 – Undertaking systematic 
reviews of research on effectiveness: CRD´s 
guidance for carrying out or commissioning 
reviews. 2nd edition, March 2001, University of 
York, UK.  
 
7 Methods/Inclusion criteria should be clarified. 
 
 We agree with reviewer #2 and added the 
following sentence (Methods, second paragraph, 
line 6): We looked for randomised trials 
comparing biphosphonates with placebo, with the 
goal of improving pain, function and quality of 
life in patients with CRPS I. 
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Abstract 
 
Objectives  Serveral studies found that biphosphonates counteract locally increased bone 
resorption and associated pain in patients with complex regional pain syndrome I (CRPS 
I). We performed a systematic review of all randomised controlled trials to assess the 
benefit of biphosphonates in the treatment of CRPS I patients with bone loss. 
Data sources We searched Medline, Embase (April 2007) and the Cochrane Library and 
screened bibliographies of included studies.  
Review methods We selected randomised trials comparing biphosphonates with placebo, 
with the goal of improving pain, function and quality of life in patients with CRPS I. Two 
reviewers independently assessed trial eligibility and quality, and extracted data. Where 
data were incomplete or unclear, conflicts were resolved with discussion and/or trial 
authors were contacted for further details. We calculated the study size weighted pooled 
mean reduction of pain intensity (measured with a visual analogue scale (VAS)). 
Results Four trials of moderate quality fulfilled our inclusion criteria. In respect to function 
and quality of life there was a trend in favour of biphosphonates but differences in outcome 
assessment impeded pooling of results. Two trials provided sufficient data to pool pain 
outcomes. Biphosphonates reduced pain intensity by 22.4 and 21.6 mm on a VAS after 4 
and 12 weeks of follow-up. Data on adverse effects were scarce.  
Conclusions The very limited data reviewed showed that bisphosphonates have the 
potential to reduce pain associated with bone loss in patients with CRPS I. However, at 
present there is not sufficient evidence to recommend their use in practice.  
250 words 
Abstract
Fig. 1: Study flow from identification to final inclusion of studies
Total citations identified from electronic databases 
(PubMed, Embase, Cochrane Central)
n = 1767
Studies retrieved for detailed analysis:
- from electronic databases n=9
- from hand searching n=7
Total n = 16
All studies identified n = 4
From electonic databases n = 4
From hand searching n = 0
Studies providing enough data n = 4
Excluded after full text assessment:
No RCT‘s n=12
Total n = 12
Citation excluded after screening titles n = 1751
Figure
Author,year Number of subjects 
(Intervention/Control)
Active component, dosage, 
administration
Duration of exposure Outcomes Follow up duration Side effects Results
Adami, 1997 20 (10/10) Alendronate 7.5mg intrave-
nous
3 days, after 14 days 
open labelled for all 
participants for 3 days
VAS (spontaneous pain and 
tenderness), arbitrary score for 
motion (O-4) assessed by 
physician, circumference (skin 
labelling), bone mineral con-
tent
Twice before treat-
ment, 2 and 4 weeks
3 patients from 
control group 
with fever 
 Intervention group: spontaneous 
pain, tenderness, swelling was sta-
tistically significant decreased 
from baseline, also when com-
pared to first 14 days of control 
group and from week 2 to 4. Im-
provement of motion.
 Control group: no relevant symp-
tomatic changes after first of 14d 
follow up, but response to open 
alendronate therapy given after-
wards.
 Bone mineral content was lower 
in 12 patient with affected hand.
Varenna, 2000 32 (15/17) Clondronate 300mg/d intra-
venous
10 days VAS, clinical global assess-
ment (0-3), efficacy verbal 
score, hydroxyprolin/kreatinin 
ratio
Before treatment, 40 
days, 90 days, 180 
days, (phone :9 and 
12 months)
3 patients from 
control group 
with asympto-
matic hypcal-
cemia
 Intervention group with signifi-
cant differences in all clinical va-
riables.
 Pooling results of all 32 patients 
after clondronate: 30 patients sig-
nificantly improved.
 Inverse correlation between base-
line hydroxyprolin/kreatinin ratio 
and decrease of VAS were found 
after 90 days (predictive factor).
Manicourt, 
2004
39 (19/20) Alendronate 40mg/d orally 8 weeks, 4 weeks 
nontherapeutic period, 8 
weeks open extension
VAS, tenderness (dolorime-
ter), edema (circumference), 
joint mobility (goniometer), 
N-Telopeptide
4,8,12,16,20,24 
weeks
One drop out 
from controll 
group due to 
gastrointestinal 
side effect 
Alendronate group marked and 
sustained improvement: pain, pres-
sure tolerance, joint mobility, N-
Telopeptide
Robinson, 2004 27 (14/13) Pamidronate 60mg intrave-
nous
Single infusion VAS, global assessment of 
disease severity score, SF-36
1,3 months 5 patients from 
treatment group 
and two patients 
from control 
group with 
influenza typed 
symptoms, 2 
patients from 
control group 
with infusion 
site reaction
 Improvement in pain score, pa-
tient’s global assessment of dis-
ease severity score and physical 
function in intervention group at 3 
months
 Improvement in physical function 
at 1 and 3 months
Table 1: Summary of included trials
Table
Descriptors
Author/Year: Adami/1997 Varenna/2000 Manicourt/2004 Robinson/2004
External Validity
Population 1 1 1 1
Intervention(s) 1 1 1 1
Outcomes 1 1 1 1
Duration of follow-up 1 1 1 1
Assessment of adverse effects 1 1 1 1
Internal Validity
Selection of a prognostically homogenous study population 2 3 1 3
Blinding of persons who assess inclusion criteria 2 4 4 4
Pre-stratification on prognostically relevant variables 4 4 4 3
Random allocation (description of procedure) 2 1 1 2
Registration of loss to follow-up 1 1 1 1
Blinding of patients 1 1 1 1
Table
Blinding of persons(s) who implement interventions 1 1 4 1
Registration of co-interventions that bear on outcome for each group 2 1 3 3
Blinding of persons(s) who assess treatment effects 4 1 4 4
Check to what extent blinding was successful 2 2 4 2
Data description and analysis
Measures of central tendency and their confidence intervals 1 1 1 1
Statistical methods 1 1 1 1
The way missing values were dealt with 2 3 3 1
An intention to treat analysis 2 2 2 1
The distributions of baseline characteristics 3 1 1 1
The way any unbalance in prognostic variables was adjusted for(if deemed 
necessary)
2 1 2 1
Compliance
Compliance (dose, timing) 1 1 1 1
1: appropriately addressed, 2: partially addressed, 3: inappropriately addressed, 4 not addressed
Table 2: Methodological quality assessment of included studies
